(Press-News.org) Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib), were much less likely to suffer a stroke after undergoing heart surgery if doctors concurrently performed an additional procedure, called left atrial appendage occlusion (LAAO), according to the results of a trial presented at the American College of Cardiology's 70th Annual Scientific Session.
AFib increases a person's risk of stroke or systemic embolism, which are life-threatening conditions caused by blood clots blocking an artery. It has been hypothesized that the blood clots that cause these conditions often originate in the left atrial appendage, a small sac on the upper left chamber of the heart. LAAO is a procedure to seal off this small sac, thus reducing the risk that a dangerous clot will form.
In this trial, LAAO lowered the risk of stroke or systemic embolism, the primary endpoint, by 33% overall in patients with AFib or atrial flutter. After the first 30 days following the procedure, patients who received LAAO were 42% less likely to suffer a stroke over long-term follow-up than those who did not receive LAAO. The trial was stopped early due to the strength of the observed benefits from the procedure.
"This study confirms a new paradigm for stroke prevention for patients with atrial fibrillation," said Richard Whitlock, MD, PhD, a cardiac surgeon at McMaster University in Ontario, Canada, and the study's lead author. "The additive benefit of surgical LAAO on top of blood thinners has now been proven. There is no question that patients who are undergoing heart surgery and have elevated stroke risk and atrial fibrillation should have their atrial appendage occluded in their cardiac surgery."
Researchers in LAAOS III enrolled 4,811 patients undergoing heart surgery at 105 centers in 27 countries. About two-thirds of the trial participants underwent valve surgery and 20% underwent coronary artery bypass graft surgery. All the patients had documented AFib or atrial flutter and a CHA2DS2-VASc score of two or higher, indicating an elevated risk of stroke. Half of the participants were randomly assigned to receive LAAO at the time of their heart surgery. All patients received standard anticoagulant medications (blood thinners) to reduce the risk of harmful clots after surgery.
After a median follow-up of 3.8 years, 4.8% of patients who received LAAO and 7% of patients who did not receive LAAO had suffered a stroke, a difference that was highly significant in favor of LAAO. The difference was even more pronounced after the first 30 days following surgery. Strokes occurring soon after surgery typically have causes beyond AFib, such as calcium from blood vessels; thus, the true impact of LAAO on the risk of stroke from AFib is best seen after that early period, Whitlock said.
The results were consistent across all subgroups analyzed, with LAAO bringing the same benefits regardless of geographic location, sex, age, type of AFib, type of blood thinner used or other variables. On average, the procedure added less than 10 minutes to the heart surgery and demonstrated safety both in the short and long term.
"We were ecstatic to see these results," Whitlock said. "This trial opens a new option for treatment of these patients by layering a mechanical approach--occlusion--on top of a medical approach. Instead of a tension between anticoagulation and occlusion, we need to start thinking about using these as additive approaches when patients are at high risk for stroke. This is a procedure that's done once, and it keeps giving a benefit over time. This is going to prevent thousands of strokes."
Since LAAO procedures in the study were performed through a standard surgical approach, it is unclear whether catheter-based approaches for LAAO would bring the same benefits.
INFORMATION:
This study was simultaneously published online in the New England Journal of Medicine at the time of presentation. The study's main funding sources were the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario.
Whitlock will be available to the media in a virtual press conference on Saturday, May 15, at 10:15 a.m. ET / 14:15 UTC.
Whitlock will present the study, "The Left Atrial Appendage Occlusion Study (LAAOS) III," on Saturday, May 15, at 9:00 a.m. ET / 13:00 UTC, virtually.
ACC.21 will take place May 15-17 virtually, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC21 for the latest news from the meeting.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit ACC.org.
Media Contacts
Nicole Napoli
202-669-1465
nnapoli@acc.org
Thy-Ann Nguyen
703-479-3642
thyann.nguyen@curastrategies.com
The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks. Findings from the PARADISE-MI trial were presented at the American College of Cardiology's 70th Annual Scientific Session.
The study is the first large trial to examine whether sacubitril/valsartan can reduce heart failure and associated hospitalizations and deaths in patients post-heart attack who face a high risk of developing heart failure. Patients taking sacubitril/valsartan were about 10% less likely than those ...
Researchers found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg), also called baby aspirin, versus 325 mg of daily aspirin, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.
Aspirin is the most common medication for people with established cardiovascular disease--for example, those who have had a heart attack, a stent placed or bypass surgery--to help prevent another heart attack, stroke or premature death. But despite aspirin's proven and widespread use, there has been no evidence as to whether low-dose aspirin (81 mg) or regular-strength (325 mg) aspirin is ...
Two months after undergoing renal denervation (RDN), patients with high blood pressure who did not respond to treatment with multiple medications had a greater reduction in daytime systolic blood pressure than patients who did not receive RDN, with no difference in major adverse effects, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
Patients who received RDN--a procedure that delivers energy to overactive nerves in the kidneys to decrease their activity--saw a median reduction of 8 mmHg in their daytime ambulatory systolic blood ...
The coronavirus pandemic has upended nearly every aspect of everyday life and continues to have devastating effects worldwide. It has also taken a significant toll on cardiovascular clinicians, many of whom provide direct care to patients with COVID-19, according to results of a new survey presented at the American College of Cardiology's 70th Annual Scientific Session.
Among those surveyed, burnout increased from 20% to 38% during the peak of the pandemic. Rates of burnout pre- and peak COVID-19 increased across all members of the cardiology team and was particularly striking among cardiovascular team members, ...
Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long-term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy (DAPT) following the insertion of a coronary stent. After two years of follow-up, chronic maintenance therapy with clopidogrel resulted in a 30% reduction in deaths, heart attacks, strokes or major bleeding events, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
"These data ...
Using more sensitive and frequent repeat testing of a blood test that indicates heart injury to guide the treatment of low-risk patients with symptoms of a possible heart attack resulted in patients being discharged earlier and receiving fewer cardiac stress tests but did not improve patient outcomes after one year, according to research presented at the American College of Cardiology's 70th Annual Scientific Session. In fact, a subset of patients receiving this more sensitive and frequent blood testing protocol were more likely to have a heart attack or to die during the one-year follow-up period compared with patients whose treatment was informed by the results of conventional blood testing procedures.
Troponins are proteins found in ...
Among patients who had a cardiac stent inserted after a heart attack, switching to less-potent dual antiplatelet therapy (DAPT) after 30 days was safer and more effective in preventing adverse events a year later than continuing on a high-potency DAPT regimen, according to data presented at the American College of Cardiology's 70th Annual Scientific Session.
"We have shown that, in patients who have had a heart attack and who've been treated with newer-generation stents and guideline-recommended medical therapy, de-escalation of DAPT by switching from ticagrelor to clopidogrel is completely safe and more effective than continuing to treat patients with ticagrelor," said Kiyuk Chang, MD, professor of Cardiology, Division of Internal Medicine at the Catholic University of ...
People with extremely high levels of triglycerides (a type of fat in the blood) and a specific genetic profile saw a substantial reduction in triglycerides after taking the human monoclonal antibody evinacumab compared with those taking a placebo, in a study presented at the American College of Cardiology's 70th Annual Scientific Session.
Severe hypertriglyceridemia is a rare disorder that causes extremely high levels of triglycerides, an accumulation of fat in the blood that can lead to heart, liver and pancreatic disease. People with severe hypertriglyceridemia commonly have triglyceride levels of 1,000 mg/dL ...
Patients at high risk for cardiovascular events who had the highest levels of eicosapentaenoic acid (EPA) in their blood one year after taking daily omega-3 carboxylic acid, a prescription-grade fish oil, had similar rates of major cardiovascular events as people taking a corn oil placebo, according to a secondary analysis of the STRENGTH trial presented at the American College of Cardiology's 70th Annual Scientific Session. Researchers also found no increase in cardiovascular events among patients with the highest levels of docosahexaenoic acid (DHA) compared to placebo.
The impetus for this post-hoc analysis was to further examine the strikingly divergent results between STRENGTH and REDUCE-IT, another large, randomized clinical trial that used a ...
Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session. The researchers, while acknowledging the results were not statistically significant, said they were encouraged by the lower numbers of organ failure and deaths observed in patients treated with dapagliflozin and by favorable safety ...
